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is a potentially curative modality of therapy for malignant and
non-malignant diseases. As a consequence of the improvement of
supportive measures over recent years (new antibiotics and anti-fun-
gal drugs, increasing experience of HSCT centers, identification of
better donors for unrelated transplants), a increasing number of
long term survivors is at risk for late complications. Secondary ma-
lignancies are described as important causes of late morbidity and
mortality after HSCT. The aim of this study is reporting the inci-
dence and mortality from secondary malignancies over 30 years in
a single center in Brazil.
Patients and Methods: We retrospectively analyzed through our
database 1682 patients submitted to HSCT at the BMT center
from Federal University of Parana from January 1979 to December
2009. We could identify 28 cases of secondary malignancy. Patient
characteristics are summarized in table 1.
Table 1. Patient’s Characteristics
Gender n (%)Male 19
Female 09
Conditioning
Myeloablative 26
Nonmyeloablative 02
Stem cell source
Bone marrow 26
Cord blood 02
HLA match
matched 26
mismatched 02
Diagnosis
Fanconi Anemia 14
Chronic Myeloid Leukemia 6
Myelodisplastic syndrome 2
Severe Aplastic Anemia and PNH 2
Lymphoid malignancies 2
others 2
Graft versus Host Disease
Acute 10 (35)
Chronic 20 (71)Results: Cumulative incidence of secondary malignancy after HSCT
was 2,0%60,5. From 28 cases, 14 had head and neck cancer (tongue)
(50%); 5 post transplant lymphoproliferative disorders related to EBV
(PTLD), three patients had gastrointestinal tract malignancies (esoph-
agus/stomach), three skin cancers (2 basocelular carcinomas and 1ma-
lignant melanoma), and other four cases involving respectively uterus,
lung, CNS and secondary Acute Myeloid Leukemia. With a median
follow-up of 10 years (2-21), overall survival was 72% for patients
with secondary malignancy. However, this curve does not reach a pla-
teau, meaning that those patients are still at risk for death in opposition
to patients without secondary malignancy. Median time from HSCT
to diagnosis was 6.8 years. From 28 patients, 13 (46,5%) died because
of the secondary malignancy. The remaining 15 patients are alive with
no evidence of malignancy in their last follow-up. Prevalence of
chronic graft-versus-host-disease (GVHD) in the secondary
malignancy patient population was 71%.
Conclusion: Secondarymalignancies were important causes of mor-
bidity and mortality after HSCT in our center, similarly to other re-
ports from literature. Incidence was higher among Fanconi anemia
patients with oral chronic graft versus host disease. Identification
of risk factors, prevention, early intervention and close follow up
of this complication are very important measures for long term
survivors of HSCT.237
LONG-TERM SURVIVORSHIP AFTER ALLOGENEIC HEMATOPOETIC CELL
TRANSPLANTATION: STILL ONGOING NON RELAPSE RELATED MORTAL-
ITY & MORBIDITY
Arat, M., Topcuoglu, P., Soydan, E.A., Arslan, €O, €Ozcan, M., Ilhan, O.,
Akan, H., Beksac, M., Konuk, N., Uysal, A.V., Koc, H., Gurman, G.
Ankara University Faculty of Medicine, Ankara, TurkeyAs the number of long-term survivors after allogeneic hematopoi-
etic cell transplantation (allo-HCT) continue to increase, many stud-
ies have been initiated for clinical evaluations and quality-of-life
assessment. We aimed to evaluate disease status, survival probability
and late-transplant-related complications in patients surviving 5 or
more years after allo-HCT in this retrospective single cohort study.
Between 1989 and 2005 total 484 patients underwent allo-HCT
from their HLA-identical relatives. Of 194 long term survivors,
173 (91 M/82 F) were evaluated.
Results:Median age at transplantation was 31 years (range, 14-51).
Their diagnosis was mainly (90%)AML and CML. We used mainly
MAC regimen (90%) and the patients received 52% PBSC. Median
follow-up after allo-HCT was 9.8 years (5.1-20.6 ys). The incidence
of acute and chronic GvHD was 46% and 76.3%, respectively. At
their last control, 36.9% of the patients had still findings related
with chronic GvHD. But only 10 patients (15.6%) were still using
an immunosupresive agent. Twenty-eight patients with chronic
GvHD continued inhaler treatment and was frequently hospitalized
due to non-infectious obliterative pulmonary complications. In pa-
tients with chronic GvHD89% (n5 57) had dry-eye and one patient
underwent cornea transplantation. Cataract was developed in 10 pa-
tients. We observed avascular bone necrosis in 10 patients. Autolo-
gous bone graft was replaced in one of them. Secondary
malignancy was detected in 4 patients. The frequencies of the devel-
opment of dislipidemia, hypertension and type II diabetes mellitus
were 34.7%, 20.8% and 7.5 %, respectively. The social and marital
statuses of the patients were summarized in table 1. Fifteen men
(21.2%) who married at pre- or post-transplant period had become
father to a baby after allo-HCT. The relapse of underlying disease
was detected in 26 patients (only six after 5 years). We performed
a second allo-HCT for relapse (n 5 4) or secondary malignity (n
5 1) using thesame donor. The estimated probabilities of DFS and
OS at 10 and 15 years were 82.1%63.1, 72.3%65.2 and 92.9% 6
2.18, 81.7% 66.1, respectively. In conclusion, mortality due to
transplant-related complications is decreasing in long term survi-
vors. Relapse rate is decreasing dramatically. The rise in cardiovascu-
lar complications is important. Long-term allotransplant
survivorship requires a carefull follow-up both for medical and still
ongoing social problems.
Variables N (%)cGVHD 64/109 (59%)
dry eye 57 (32.9%)
BOS/BOOP 28 (16.2%)
Osteopenia/Osteoporosis 61 (74.4%)
median BMI 25 (12-40)
Obesity (BMI>29) 32 (18.5%)
Low BW (BMI<18.5) 7 (4.02%)
mariage pretx 105 (60.9%)
mariage posttx 26 (15%)
single 39 (22.5%)
fertility 15 (8.6%)
Active working 28.9%
house wife 33.5%
retired 18%
student 2.3%
relapse <5y 20 (11.3%)
relapse >5y 6 (3.4%)238
STABLE PULMONARY FUNCTION OBSERVED OVER TIME IN RECIPIENTS
OF MYELOABLATIVE DOUBLE CORD BLOOD TRANSPLANT: A SINGLE
CENTER EXPERIENCE
Milano, F.1, Riffkin, I.1, Laura, L.1,4, Gutman, J.2, Chien, J.1,4,
Delaney, C.1,3 1Fred Hutchinson Cancer Research Center, Seattle, WA;
2University of Colorado, Denver, CO; 3University ofWashington, Seattle,
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Background: Pulmonary complications, which develop in 40% to
60% of transplant recipients, represent a major cause of morbidity
S242 Poster Session Iand mortality after allogeneic hematopoietic stem cell transplanta-
tion. However very little is known about pulmonary dysfunction
following myeloablative umbilical cord blood transplantation
(CBT).
Methods: We performed a retrospective analysis of data prospec-
tively collected between January 2006 and December 2009 from pa-
tients who underwent double CBT following myeloablative
conditioning with total body irradiation (1320 cGy), cyclophospha-
mide (60 mg/kg iv daily for 2 days) and fludarabine (40 mg/m2 iv
daily for 3 days). Pulmonary function tests (PFTs) were performed
pretransplant and at day 80 and 1 year after transplantation. Lung
function score (LFS) categories were calculated by combining
FEV1 and DLCO and categorized 0 5 normal, 1 5 mildly abnor-
mal, 25moderately abnormal and 35 severely abnormal as defined
by NIH recommendations.
Results:Of 49 patients, 13 (26%) were excluded because either died
prior to or were without day 80 PFTs and 3 (6%) due to lack of pre-
transplant PFTs. Thirty three patients (68%) were included in the
final analysis. The median age and follow-up were 24.2 years (IQR
15.2-38) and 789 days (IQR 335-1087), respectively. Twenty-three
(70%) patients had PFTs at 1 year. Table 1 shows both the distribu-
tion and changes of the PFT data collected at day 80 and 1 year after
transplantation. At 1 year 60% of patients were in LFS category 1
and no one in category 3. The rate of lung function decline (ex-
pressed as the annualized rate of FEV1 decline) from baseline to 1
year after CBT was \ 5% in 78% patients. Four (12%) patients
had abnormal PFTs with an obstructive pattern (AFO) in 3 (9%)
and a restrictive pattern (RP) in one (3%). In 2 of the 3 patients
with obstruction, the obstructive pattern resolved after corticoste-
roid therapy.
Conclusions: To our knowledge this is the first study to describe
pulmonary function after double CBT. No clinically significant de-
creases in all PFTs during the first year were observed. In partic-
ular the majority of patients presented a minimal rate of FEV1
decline. The incidence of AFO and RP was lower than that usually
observed after transplantation from unrelated donors. Future con-
firmatory studies should include more patients and a comparison
group.
Table 1. Comparison of change in pulmonary function
parameters obtained pretransplant, at day 80, and one year
after transplant.
FEV1 FVC FEV/FVC TLC DLcoMean value of PFTs:Pretransplant 91.4 ± 12.8 97.5 ± 14.4 0.81 ± 0.12 97.9 ± 12.8 75.7 ± 13.1Day 80 86.0 ± 12.9 91.7 ± 12.2 0.79 ± 0.08 94.7 ± 12.0 71.1 ± 16.21 year 88.6 ± 11.3 91.7 ± 15.1 0.84 ± 0.08 92.9 ± 12.5 70.1 ± 18.9Mean Change of PFTs:Day 80 -6.4 ± 11.3 -6.9 ± 11.3 -1.8 ± 5.7 -4.3 ± 6.6 -5.3 ± 11.81 year -3.6 ± 10.7 -3.0 ± 11.2 0.4 ± 8.6 -2.2 ± 10.1 -7.4 ± 14.3239
HIGH INCIDENCE OF RADIATION INDUCED CAVERNOUS HEMANGIOMA
(RICH) IN LONG TERM SURVIVORS WHO UNDERWENT BMT WITH RADI-
ATION THERAPY DURING CHILDHOOD OR ADOLESCENCE
Koike, T.1, Yanagimachi, N.2, Yabe, H.3, Yabe, M.3, Morimoto, T.1,
Simizu, T.1, Ishiguro, H.1, Takakura, H.1, Kato, S.3 1Tokai University
Hospital, Isehara, Kanagawa, Japan; 2Tokai University Hospital, Isehara,
Kanagawa, Japan; 3Tokai University Hospital, Isehara, Kanagawa,
Japan
Introduction:Radiation induced cavernous hemangioma (RICH) is
a late complication of cerebral radiation therapy. An increased num-
ber of long term surviving blood and marrow transplantation (BMT)
recipients have recovered from their primary diseases but are at risk
of RICH.
Methods:We investigated 67 patients who underwent BMT during
childhood or adolescence. We evaluated RICH numbers, size, loca-
tion and their annual changes. Furthermore we developed scoringsystem of RICH in order to classify the severity. MRI of the brain
was performed annually for 5 to 27 years after BMT, including gra-
dient-echo sequence (T2* weighted image). RICH SCORE 1-4 is
designated as mild, 5-9 as moderate and 10 or more as severe.
Results: Twenty-six patients (38.8%) was diagnosed RICH. All
cases received TBI as conditioning of BMT and/or cranial radiation
(CR) prior to BMTas treatment of primary disease. RICHwas found
in 26/48 (54.2%) who received TBI and/or CR, and was not found in
any of 19 patients without radiation therapy to the brain. Total dose
to the brain was 10-36Gy. RICH SCORE ranged 1-18 points (me-
dian 4 points). Small RICHs tended to be recognized only by T2*
weighted image, but not by routine imagingmethods. Classifications
of the severity were mild in 14 patients, moderate in 8 patients and
severe in 4 patients. Severity was correlated with higher radiation
dose and/or with younger ages at transplantation. One case
developed giant RICH more than 40mm.
Conclusion: Since all of those patients did not show RICH before
BMT and all positive patients had a history of radiation therapy to
the brain, the cause of RICH in those patients was considered to
be radiation. Careful and long term evaluation with MRI including
T2* weighted image is necessary in BMT recipients who received
radiation therapy prior and/or during BMT.240
THE RELATIVE IMPORTANCE OF INPATIENT LAY CARE-PARTNERS TO
PATIENT ILLNESS ADJUSTMENT IN ALLOGENEIC BMT
Foster, L.W.1, McLellan, L.2, Rybicki, L.2, Dabney, J.2, Cooper, M.2,
Bolwell, B.2 1Cleveland State University, Cleveland, OH; 2Cleveland
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Previously we reported a retrospective study describing the posi-
tive impact of having an inpatient lay care-partner (CP) on patient
survival in allogeneic BMT. To better explain this phenomenon
we launched a prospective study comparing illness adjustment be-
tween allo BMTpatients with andwithout an inpatient lay CP. Study
patients were a subset of acute leukemia patients from a larger pro-
spective study (N5 164) that verified patients with a CP had signif-
icantly better rates of survival (P 5 0.017). Of the 32 enrolled
patients, 17 had a CP; 15 did not. Utilizing a modes of illness adjust-
ment (MIA) interview schedule, patients were interviewed pre-ad-
mission and 100 days post-transplant by a social worker; taped
interviews were scored by two other social workers. The Psychoso-
cial Assessment of Candidate for Transplant (PACT) Scale was com-
pleted by the social worker. Patients completed FACT-BMT
(quality of life), Profile of Mood States-Short Form (POMS), and
Brief COPE.
Majority of CPs were female, a spouse or parent, and were with
patients a median of 7 hours a day and a median of 85% of inpa-
tient days. There were no significant differences between patients
with and without CPs on patient demographics and medical vari-
ables. Patients with a CP had significantly better scores on the ini-
tial PACT scale rating of candidate quality for transplant (P 5
0.022) and on sub-scale of family or support system availability
(P 5 # 0.001).
Illness adjustment included four modes: accommodation, second-
ary gains, denial, resignation, and two summed variables: accommo-
dation1 secondary gains and denial1 resignation. Variables did not
differ significantly between groups at baseline, although at post-
transplant resignation (P 5 0.009) and denial 1 resignation (P 5
0.036) were significantly smaller among patients with no CP. Also,
from pre- to post-transplant, denial (P 5 0.049) and denial1 resig-
nation (P5 0.044) decreased among patients without a CP, suggest-
ing these patients may have become less oppositional in adjusting to
illness.
MIA did not correlate significantly with patient survival but sur-
vival correlated significantly with CP presence (P 5 0.039) and CP
frequency. 75% (P5 0.019). MIA correlated significantly with se-
lect items on FACT-BMT, POMS, and Brief COPE. Better scores
on these scales associated with complimentaryMIA and worse scores
associated with oppositional MIA. Essential is a support program for
patients as well as CPs to improve quality and outcome of the BMT
experience.
